Notably, vaccines for the treatment of allergy also rely largely on the induction of blocking IgG, as do emerging AIT approaches aiming to achieve protective effects whilst limiting the risk of IgE-mediated side effects through the use of allergen components or allergoids modified to reduce allergenicity yet maintain an ability to mount humoral responses towards functional blocking IgG (56–60). The gene discussed is IGHE; the disease is allergic disease.